Core Viewpoint - The company has established a dual-track strategy focusing on both invasive and non-invasive medical applications, particularly in the field of brain-computer interfaces (BCIs) [1] Group 1: Non-Invasive Medical Applications - The company is currently integrating existing rehabilitation devices with brain-computer interfaces to enhance product functionality and is actively promoting commercialization [1] - In addition to the medical field, the company is exploring non-medical applications in various sectors, including education, elderly care, and health [1] - In the education sector, the company has launched a brain-computer interface biofeedback system aimed at attention detection and training [1] Group 2: Invasive Medical Applications - The company is constructing a research verification center and an animal testing center for its brain-computer interface technology, which are crucial for its strategic layout in this field [1] - These two centers will create a complete innovation chain from basic research to technology verification and result transformation [1]

Core Viewpoint - The brain-computer interface (BCI) sector in the A-share market has seen significant gains, driven by recent government policies that elevate BCI from a research field to a national industry strategy [1][2]. Group 1: Market Performance - On August 12, stocks in the BCI sector rose sharply, with Mailland increasing by over 18%, Xiangyu Medical by 12%, and Qisheng Technology by 10% [1]. - Other notable stocks in the sector, such as Innovation Medical, Chengyitong, and Beiyikang, also experienced gains [1]. Group 2: Policy Developments - A joint announcement from seven government departments, including the National Health Commission and the Drug Administration, has been made to promote the innovation and development of the BCI industry, marking a significant policy shift [2]. - Multiple policies have been implemented this year to accelerate the clinical application of BCI technology, including the establishment of pricing guidelines for BCI services by the National Medical Insurance Administration [3]. Group 3: Company Strategies - Chengyitong has established a dual-track strategy focusing on both invasive and non-invasive BCI technologies, integrating existing rehabilitation devices with BCI for product upgrades and exploring applications in education, elderly care, and health [4]. - Sanbo Brain Science is actively monitoring BCI technology trends and is focusing on invasive and semi-invasive applications, while also planning to establish a brain science innovation fund for industry investment and collaboration [6].

Core Viewpoint - The company has established a dual-track strategy of "invasive and non-invasive" approaches in its business operations [1] Non-Invasive Medical Sector - The company is currently integrating existing rehabilitation equipment with brain-computer interface (BCI) technology to enhance product functionality and is actively promoting commercialization [1] - Beyond the medical field, the company is exploring applications in "non-medical" scenarios, including education, elderly care, and health [1] - In the education sector, the company has launched a BCI biofeedback system aimed at attention detection and training [1] Invasive Medical Sector - The company is constructing a brain-computer interface technology research and validation center along with an animal testing center, which are crucial for its strategic layout in the BCI field [1] - These two centers will create a complete innovation chain from "basic research - technology validation - achievement transformation" [1]

人民财讯8月12日电，诚益通（300430）8月12日在互动平台表示，公司已确立"侵入式与非侵入式"双轨 并行的战略布局，在非侵入式严肃医疗赛道，公司目前主要将现有康复设备与脑机接口进行结合，升级 现有产品功能，并积极推进相关商业化落地；除医疗领域外，公司也在积极探索"非医疗"场景的应用， 包括教育、养老、健康等多个领域，其中，在教育领域，公司已推出面向专注力检测与训练的脑机接口 生物反馈系统。在侵入式领域，公司脑机接口技术研究验证中心与动物实验中心正在建设中，作为公司 在脑机接口领域的重要战略布局，两大中心将构建"基础研究—技术验证—成果转化"的完整创新链条。 ...

诚益通（300430.SZ）8月12日在投资者互动平台表示，公司已确立"侵入式与非侵入式"双轨并行的战略 布局，在非侵入式严肃医疗赛道，公司目前主要将现有康复设备与脑机接口进行结合，升级现有产品功 能，并积极推进相关商业化落地；除医疗领域外，公司也在积极探索"非医疗"场景的应用，包括教育、 养老、健康等多个领域，其中，在教育领域，公司已推出面向专注力检测与训练的脑机接口生物反馈系 统。在侵入式领域，公司脑机接口技术研究验证中心与动物实验中心正在建设中，作为公司在脑机接口 领域的重要战略布局，两大中心将构建"基础研究-技术验证-成果转化"的完整创新链条。 每经AI快讯，有投资者在投资者互动平台提问：请问公司下属脑连科技的bci脑控机器人相关开发进度 如何？有哪些储备技术和产品？ （文章来源：每日经济新闻） ...